Arcus Biosciences Debt to Equity Ratio 2017-2022 | RCUS
Current and historical debt to equity ratio values for Arcus Biosciences (RCUS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Arcus Biosciences debt/equity for the three months ending March 31, 2022 was 0.00.
| Arcus Biosciences Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2022-03-31 |
$0.75B |
$0.80B |
0.94 |
| 2021-12-31 |
$0.75B |
$0.84B |
0.89 |
| 2021-09-30 |
$0.30B |
$0.54B |
0.55 |
| 2021-06-30 |
$0.29B |
$0.61B |
0.49 |
| 2021-03-31 |
$0.27B |
$0.67B |
0.41 |
| 2020-12-31 |
$0.27B |
$0.50B |
0.54 |
| 2020-09-30 |
$0.27B |
$0.54B |
0.49 |
| 2020-06-30 |
$0.05B |
$0.43B |
0.12 |
| 2020-03-31 |
$0.04B |
$0.14B |
0.25 |
| 2019-12-31 |
$0.04B |
$0.16B |
0.24 |
| 2019-09-30 |
$0.04B |
$0.18B |
0.22 |
| 2019-06-30 |
$0.04B |
$0.20B |
0.22 |
| 2019-03-31 |
$0.04B |
$0.22B |
0.17 |
| 2018-12-31 |
$0.04B |
$0.24B |
0.17 |
| 2018-09-30 |
$0.04B |
$0.25B |
0.17 |
| 2018-06-30 |
$0.04B |
$0.26B |
0.15 |
| 2018-03-31 |
$0.04B |
$0.27B |
0.15 |
| 2017-12-31 |
$0.04B |
$0.15B |
0.24 |
| 2017-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2017-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2017-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2016-12-31 |
$0.00B |
$0.00B |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.901B |
$0.383B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
